Stay updated with breaking news from Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
07.12.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that it will stop the Phase 3 KEYLYNK-008 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, for ...
/PRNewswire/ -- Qilu Pharmaceutical presented the latest results of the single-arm, phase II pivotal clinical study for iparomlimab (QL1604), an innovative...
BOTHELL, Wash.--(BUSINESS WIRE)--Dec 6, 2023--
Merck a leading science and technology company today announced a license agreement with Abbisko Therapeutics Co. Ltd. Shanghai China for pimicotinib ABSK021 which is currently being evaluated in a Phase III study for the treatment of tenosynovial giant cell tumor TGCT.
– STELLAR-305 is Exelixis’ first pivotal study in squamous cell carcinoma of the head and neck – – Trial will evaluate the potential of inhibition of VEGF, MET and AXL, which are elevated...